These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37423117)

  • 21. Targeting phosphoglycerate dehydrogenase in multiple myeloma.
    Elsaadi S; Steiro I; Abdollahi P; Vandsemb EN; Yang R; Slørdahl TS; Rø TB; Menu E; Sponaas AM; Børset M
    Exp Hematol Oncol; 2021 Jan; 10(1):3. PubMed ID: 33397437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway.
    Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y
    Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
    Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
    Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
    J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
    Csizmarik A; Keresztes D; Nagy N; Bracht T; Sitek B; Witzke K; Puhr M; Tornyi I; Lázár J; Takács L; Kramer G; Sevcenco S; Maj-Hes A; Jurányi Z; Hadaschik B; Nyirády P; Szarvas T
    Int J Cancer; 2022 Oct; 151(8):1405-1419. PubMed ID: 35689436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer.
    Liu J; Zhao Y; He D; Jones KM; Tang S; Allison DB; Zhang Y; Chen J; Zhang Q; Wang X; Li C; Wang C; Li L; Liu X
    Cell Rep Med; 2023 Apr; 4(4):101015. PubMed ID: 37075701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
    Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
    Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Luo M; Zhang Y; Xu Z; Wu C; Ye Y; Liu R; Lv S; Wei Q
    Cell Death Discov; 2022 Nov; 8(1):471. PubMed ID: 36446767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
    Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
    Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy
    Zhou X; Zou L; Liao H; Luo J; Yang T; Wu J; Chen W; Wu K; Cen S; Lv D; Shu F; Yang Y; Li C; Li B; Mao X
    Acta Pharm Sin B; 2022 Feb; 12(2):692-707. PubMed ID: 35256940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin in Overcoming Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    Simpson K; Allison DB; He D; Liu J; Wang C; Liu X
    J Pharmacol Exp Ther; 2024 Oct; ():. PubMed ID: 39379144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
    Pilling AB; Hwang C
    Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.
    Zhao J; Zhao Y; Wang L; Zhang J; Karnes RJ; Kohli M; Wang G; Huang H
    Oncotarget; 2016 Jun; 7(25):38551-38565. PubMed ID: 27221037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crosstalk of NF-κB/P65 and LncRNA HOTAIR-Mediated Repression of MUC1 Expression Contribute to Synergistic Inhibition of Castration-Resistant Prostate Cancer by Polyphyllin 1-Enzalutamide Combination Treatment.
    Xiang S; Zou P; Wu J; Zheng F; Tang Q; Zhou J; Hann SS
    Cell Physiol Biochem; 2018; 47(2):759-773. PubMed ID: 29807357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Derepression of CXCR7 indicates resistance to enzalutamide in castration resistant prostate cancer].
    Luo Y; Feng BF; Wei DC; Li MC; Han YL; Zhao JH; Lin YH; Li Q; Hou Z; Zhuang HY; Jiang YG
    Zhonghua Yi Xue Za Zhi; 2019 Apr; 99(16):1237-1240. PubMed ID: 31060163
    [No Abstract]   [Full Text] [Related]  

  • 37. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
    Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
    EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
    Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
    Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer.
    Chen X; Yin L; Qiao G; Li Y; Li B; Bai Y; Feng F
    Oncol Lett; 2020 Sep; 20(3):2997-3005. PubMed ID: 32782617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer.
    Sakamoto S; Maimaiti M; Xu M; Kamada S; Yamada Y; Kitoh H; Matsumoto H; Takeuchi N; Higuchi K; Uchida HA; Komiya A; Nagata M; Nakatsu H; Matsuyama H; Akakura K; Ichikawa T
    J Clin Med; 2019 Apr; 8(4):. PubMed ID: 30978937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.